Huiqin Dou1, Dongyan Hu1, Chileong Lam1, Yunsheng Liu1, Xiuwen Wang1, Wendong Zhang1. 1. 1 Department of Stomatology, 2 Department of Clinical Oncology, Qilu Hospital of Shandong University, Jinan 250012, China ; 3 Department of Clinical Oncology, Conde S. Januario General Hospital, Macao, China.
Abstract
BACKGROUND: Nasopharyngeal carcinoma (NPC) is a common malignancy in Southeast Asia, however, a full consensus has not yet been reached as to the value of comprehensive treatment for NPC. This study was designed to evaluate the epidemiological characteristics of NPC and their prognostic value, as well as the long-term efficacy of NPC treatment. PATIENTS AND METHODS: A total of 248 patients, with different stages of NPC, were included in this study. RESULTS: The 5-year overall survival (OS) rates for patients in stages I, II, III and IV were 90.48%, 76.71%, 76.89% and 33.87%, respectively (P=0.000), while the respective 5-year progression-free survival (PFS) rates were 85.15%, 72.36%, 63.88% and 26.26% (P=0.000). The respective 5-year OS rates, according to stage, for the group that received radiotherapy combined with chemotherapy and for the group that received radiotherapy only were as follows: stages I and II, 81.67% and 79.59% (P=0.753); stage III, 79.91% and 70.38% (P=0.143); stage IV, 35.22% and 0% (P=0.000). The respective 5-year PFS rates in these groups were as follows: stages I and II, 75.83% and 74.98% (P=0.814); stage III, 74.08% and 42.25% (P=0.027); stage IV, 27.31% and 0% (P=0.000). CONCLUSIONS: Clinical staging appears to be the most important prognostic factor for NPC. As the stage number increases, both the 5-year OS and PFS significantly decrease. Adding chemotherapy to radiotherapy was not advantageous for patients with stage I or II NPC, however the addition of chemotherapy to radiotherapy significantly improved OS and PFS in patients with stage IV NPC. The addition of chemotherapy improved PFS, but not OS in patients with stage III NPC.
BACKGROUND:Nasopharyngeal carcinoma (NPC) is a common malignancy in Southeast Asia, however, a full consensus has not yet been reached as to the value of comprehensive treatment for NPC. This study was designed to evaluate the epidemiological characteristics of NPC and their prognostic value, as well as the long-term efficacy of NPC treatment. PATIENTS AND METHODS: A total of 248 patients, with different stages of NPC, were included in this study. RESULTS: The 5-year overall survival (OS) rates for patients in stages I, II, III and IV were 90.48%, 76.71%, 76.89% and 33.87%, respectively (P=0.000), while the respective 5-year progression-free survival (PFS) rates were 85.15%, 72.36%, 63.88% and 26.26% (P=0.000). The respective 5-year OS rates, according to stage, for the group that received radiotherapy combined with chemotherapy and for the group that received radiotherapy only were as follows: stages I and II, 81.67% and 79.59% (P=0.753); stage III, 79.91% and 70.38% (P=0.143); stage IV, 35.22% and 0% (P=0.000). The respective 5-year PFS rates in these groups were as follows: stages I and II, 75.83% and 74.98% (P=0.814); stage III, 74.08% and 42.25% (P=0.027); stage IV, 27.31% and 0% (P=0.000). CONCLUSIONS: Clinical staging appears to be the most important prognostic factor for NPC. As the stage number increases, both the 5-year OS and PFS significantly decrease. Adding chemotherapy to radiotherapy was not advantageous for patients with stage I or II NPC, however the addition of chemotherapy to radiotherapy significantly improved OS and PFS in patients with stage IV NPC. The addition of chemotherapy improved PFS, but not OS in patients with stage III NPC.
Authors: Daniel T T Chua; Jun Ma; Jonathan S T Sham; Hai-Qiang Mai; Damon T K Choy; Ming-Huang Hong; Tai-Xiang Lu; Gordon K H Au; Hua-Qing Min Journal: Int J Radiat Oncol Biol Phys Date: 2006-06-05 Impact factor: 7.038
Authors: D M Heng; J Wee; K W Fong; L G Lian; V K Sethi; E T Chua; T L Yang; H S Khoo Tan; K S Lee; K M Lee; T Tan; E J Chua Journal: Cancer Date: 1999-11-15 Impact factor: 6.860
Authors: P Teo; P Yu; W Y Lee; S F Leung; W H Kwan; K H Yu; P Choi; P J Johnson Journal: Int J Radiat Oncol Biol Phys Date: 1996-09-01 Impact factor: 7.038
Authors: A T C Chan; P M L Teo; R K Ngan; T W Leung; W H Lau; B Zee; S F Leung; F Y Cheung; W Yeo; H H Yiu; K H Yu; K W Chiu; D T Chan; T Mok; K T Yuen; F Mo; M Lai; W H Kwan; P Choi; P J Johnson Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: Anne W M Lee; W M Sze; Joseph S K Au; S F Leung; T W Leung; Daniel T T Chua; Benny C Y Zee; Stephen C K Law; Peter M L Teo; Stewart Y Tung; Dora L W Kwong; W H Lau Journal: Int J Radiat Oncol Biol Phys Date: 2005-03-15 Impact factor: 7.038
Authors: Kyong Hwa Park; Jeong Sun Kim; Yong Park; Hee Yeon Seo; Young Je Park; In Keun Choi; Sang Chul Oh; Jae Hong Seo; Chul Yong Kim; Kwang Yoon Jung; Sang Won Shin; Yeul Hong Kim; Jun Suk Kim; Nam Joon Lee Journal: Cancer Chemother Pharmacol Date: 2009-12-23 Impact factor: 3.333